Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-Siglec-10 monoclonal antibody ONC-841

A humanized monoclonal antibody directed against the immune checkpoint molecule sialic acid-binding immunoglobulin (Ig)-like lectin 10 (Siglec-10; SIGLEC10), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-Siglec-10 monoclonal antibody ONC-841 targets and binds to Siglec-10 expressed on various immune cells, including tumor-associated macrophages (TAMs) and natural killer (NK) cells, in the tumor microenvironment (TME). This prevents Siglec-10-mediated signaling, and activates NK cells, macrophages, and T cells. This abrogates Siglec-10-mediated inhibition of phagocytosis of tumor cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC), thereby killing tumor cells and inhibiting tumor cell growth. Siglec-10, an inhibitory receptor expressed on a variety of immune cells, plays an important role in tumor immune invasion through its interaction with the tumor-expressed co-stimulatory molecule CD24.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-SIGLEC10 monoclonal antibody ONC-841
Code name:ONC 841
ONC-841
ONC841
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search